1. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. (11th October 2018) Authors: Cottu, P; D'Hondt, V; Dureau, S; Lerebours, F; Desmoulins, I; Heudel, P -E; Duhoux, F P; Levy, C; Mouret-Reynier, M -A; Dalenc, F; Frenel, J -S; Jouannaud, C; Venat-Bouvet, L; Nguyen, S; Ferrero, J -M; Canon, J -L; Grenier, J; Callens, C; Gentien, D; Lemonnier, J Journal: Annals of oncology Issue: Volume 29:Number 12(2018) Page Start: 2334 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. (15th December 2017) Authors: Swain, S M; Ewer, M S; Viale, G; Delaloge, S; Ferrero, J -M; Verrill, M; Colomer, R; Vieira, C; Werner, T L; Douthwaite, H; Bradley, D; Waldron-Lynch, M; Kiermaier, A; Eng-Wong, J; Dang, C Journal: Annals of oncology Issue: Volume 29:Number 3(2018) Page Start: 646 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗